Sanofi Upgrades 2024 Business EPS Guidance To Low Single-Digit Growth At CER, Reflecting Strong Performance And Excluding Opella
Portfolio Pulse from Benzinga Newsdesk
Sanofi has upgraded its 2024 business EPS guidance to at least low single-digit growth at constant exchange rates, reflecting strong performance. The guidance excludes Opella, and currency impact is estimated to be -5.5% to -6.5%.
October 25, 2024 | 6:07 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Sanofi has upgraded its 2024 EPS guidance to low single-digit growth at constant exchange rates, excluding Opella. The currency impact is estimated to be -5.5% to -6.5%.
Sanofi's upgrade in EPS guidance indicates strong business performance, which is positive for the stock. However, the negative currency impact slightly offsets this positive outlook. Overall, the news is likely to have a positive short-term impact on Sanofi's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100